CDMO Powers 32%, But Baddi Capex and Zambia Slip Narrow the Path
CDMO revenue jumped 38.6% year-on-year, delivering on volume guidance (+20% vs high-teens promised) and holding margins at 14.5%. But near-term capex concentration (Baddi ₹43 Cr operationalizing Q1 FY28) and a three-month slip in Zambia revenue timing (H2 FY27 → Q1 FY28) raise questions on near-term visibility.
₹1,342 Cr
+31.9% YoY, +15.1% QoQ
₹1,115 Cr
+38.6% YoY (83% of total)
14.5%
vs 14.5% prior year (target: 14–15%)
₹115 Cr
+168.3% YoY, +13.5% QoQ
Akums Drugs delivered the quarter on the back of CDMO momentum. Revenue grew 31.9% year-on-year to ₹1,342 Cr, with the contract manufacturing division (₹1,115 Cr, +38.6% YoY) now representing 83% of the business. Volume growth came in at 20% on a net maturity-adjusted (MAT) basis — beating the high-teens guidance issued on the prior call — and margins held steady at 14.5%, within management's 14–15% guidance band. PAT surged 168% to ₹115 Cr, with the conversion from EBITDA (up 106% YoY to ₹195 Cr) to net profit reflecting meaningful operational leverage and reduced API losses rather than one-time items. The tension, however, sits in the near term: capex concentration for a new facility (Baddi, ₹43 Cr invested in H1) operationalizes Q1 FY28, and a three-month revenue timing slip in the Zambia CDMO contract (now Q1 FY28 instead of H2 FY27) narrow visibility through year-end.
What the numbers hold up
CDMO high-teens volume growth Q2-onwards
CDMO volume +20% on Sept net MAT; ₹1,115 Cr revenue (+38.6% YoY)
Supported (beat)
Maintain 14–15% EBITDA margin
Q2 delivered 14.5% (lower end of band); EBITDA ₹195 Cr (+106% YoY)
Supported
Zambia ~₹240 Cr revenue H2 FY27
Supplies scheduled Q4; revenue booking deferred to Q1 FY28 due to election delays
Overstated (3-month slip)
API to reach monthly EBITDA breakeven by end FY27
API EBITDA loss ₹5.7 Cr (vs ₹14 Cr Q2 FY26); 3–4 quarters to breakeven targeted
On track (improving, not yet breakeven)
What changed on this call
Zambia timing slip (downgrade): Prior guidance placed ₹240 Cr of Zambia CDMO revenue in H2 FY27. On this call, management disclosed that mid-year elections delayed government procurement sign-off. Purchase orders are now in hand, and supplies are scheduled for Q4 FY27 dispatch, but the 100–120 day shipping lag pushes revenue recognition to Q1 FY28 — a three-month slip from prior expectation.
CDMO volume beat (upgrade): Guidance from the prior call set CDMO volume growth at high-teens. The quarter delivered 20% volume growth on a net MAT basis, with September showing 50%+ utilization (a healthy absorption level). Pricing remained modest: API prices rose 2–3% quarter-on-quarter, down from 5–7% in the prior-year Q2. The volume beat was driven across existing and new customers, with no single-customer concentration disclosed.
Baddi capex timeline confirmed (new): The Baddi oral solids facility (Himachal Pradesh) is fully funded and on track. Phase 1 (6 billion units of annual capacity, ₹43 Cr capex in H1 FY27) operationalizes Q1 FY28. Management expects it to contribute 10–15% of CDMO business within three years, with phases 2–3 to follow as utilization ramps. Debt/equity funding remains flexible.
API loss narrowing (neutral): The API segment EBITDA loss came in at ₹5.7 Cr, a 60% improvement from the ₹14 Cr loss in Q2 FY26. Management reaffirmed the path to EBITDA breakeven by end FY27 (3–4 quarters from quarter-end), with focus on high-margin products and geographies. No acceleration claimed; the trajectory is orderly.
CDMO volume +20%, beating high-teens guidance; utilization 50%+
Margins held at 14.5% (14–15% band); EBITDA growth 106% YoY
Baddi phase 1 ₹43 Cr capex; operationalizes Q1 FY28 (low-cost asset)
European CDMO dossier filed; supplies to commence FY28 onwards
Zambia revenue pushed H2 FY27 → Q1 FY28 (3-month delay, election-blamed)
Baddi capex concentration; margin support contingent on utilization ramp
API segment EBITDA loss ₹5.7 Cr still material; breakeven 3–4 Q away
Domestic branded +8% YoY; PCPM 2.5 (field force investment drag temporary)
Baddi capex concentration & operational ramp
Medium₹43 Cr H1 capex; margin uplift post-Q1 FY28 operationalization dependent on utilization reaching 60%+. Delay or underutilization would compress group EBITDA by 50–100 bps.
Zambia execution & timing
Medium₹240 Cr revenue now Q1 FY28 vs. H2 FY27 prior guidance. 100–120 day shipping lag post-Q4 dispatch creates FY28 revenue realization risk if production delays.
API segment ongoing loss
Medium₹5.7 Cr EBITDA loss still a drag on group margin. Breakeven by year-end assumes product mix and price improvements; commodities volatility and competition remain.
Domestic branded growth headwind
Low8% growth lags group CAGR. Field force PCPM at 2.5; management expects recovery to 3+ as hires mature. If PCPM stalls, IPM-pace growth (mid-single digit) becomes ceiling.
Oriflame cosmetics acquisition ROI
Low₹56 Cr acquisition; expects 3x revenue uplift over 2 years (unproven). M&A integration and color cosmetics market competitiveness remain.
The market's read
The stock closed at ₹749.8 on 4 Nov 2026, trading between its 20-day SMA (₹736.64) and 50-day SMA (₹764.3), above the 200-day average of ₹607.31. The price sits 36% below its all-time high of ₹1,175.9 but 83% above its 52-week low, suggesting a sharp correction from peak valuations has already priced in execution risk. Volume trends are increasing, a signal of renewed interest.
Ownership tells a shifting story. FII holdings have halved over the past year: from 5.77% (Q4 FY26) to 1.91% (Q1 FY27), with an incremental +0.54pp gain in the most recent quarter (suggesting some stabilization post-correction). DII holdings remain robust at 13.44% (slightly down from 14.35% Q4 FY26), and promoter stake is steady at 75.26%. The FII exit during the run-up from ₹409 (52w low) to ₹838 (52w high) is a sell-on-strength signal. That early-mover FII trimming leaves the stock more promoter-and-DII backed — which is defensive but also implies less institutional tailwind if execution falters.
Read together: the big correction (36% off ATH) has created a margin of safety on fundamentals, but the FII reposition signals that growth assumptions have reset. CDMO momentum is real and beat guidance, but the stock is now priced for Baddi and Zambia execution, not upside surprise. A stumble on either front would test the ₹607 support (200d SMA level, offering structural bid).
1 · Q1 FY28 Baddi operationalization
Phase 1 oral solids (6B units) must achieve design capacity and utilization >50% within first quarter of ops. Margin support (1–2% EBITDA uplift) hinges on this. Any delays → stock test of ₹650 support.
2 · Zambia revenue booking & margin
Q4 FY27 supply dispatch must occur on schedule (no further delays). Q1 FY28 revenue recognition (~₹240 Cr, likely over 2–3 quarters as units ship) and gross margin % are the key metrics.
3 · API breakeven path
Breakeven by end FY27 (per management) means Q4 FY27 should show EBITDA inflection to <₹2 Cr loss or breakeven. Failure to achieve this signals mix/pricing headwinds; continued drag would weigh on group guidance.
Akums Drugs is a steady CDMO operator with structural tailwinds (20%+ volume growth, therapies mix improving), but Q2 is not a breakout moment — it is the maturation of a well-guided business. Management delivered on CDMO volume and margin discipline, but telegraphed near-term headwinds (Baddi capex, Zambia timing slip, API loss still material). The honest read is neither bull nor bear; it is a 12–18 month story where execution on three fronts (Baddi ramp, Zambia revenue, API breakeven) determines whether 2027 is a step-change or a steady-state year.
The number to track from here: EBITDA margin. If Baddi phases in cleanly and Zambia revenue books on schedule, the 14.5% FY27 margin should expand to 15–16% in FY28 and hold. If either stumbles, the 14–15% band becomes ceiling. That single metric summarizes the bet.
Informational and educational content only. Not investment advice.